Andson Biotech secures $3.6M in equity financing, propelling the development of their groundbreaking DynaCHIP mass spec sample prep solution. Led by CEO Mason Chilmonczyk, the funding will accelerate market introduction and support the creation of DynaMARK, advancing cell and gene therapy analytics. With a mission to revolutionize mass spectrometry, Andson Biotech is poised for impactful innovation in biotherapeutics and chemical analysis. Learn more at Andson Biotech’s website.